CTLA4 and neoplasm: Attempts to reinvigorate an anti-tumor immune response have been widely integrated into practice following the development of the immune checkpoint inhibitors (ICIs) targeted against the immune checkpoint receptors cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed death-ligand 1 (PD-L1).